Clinical Trials Browser

Lymphoma, Multiple Myeloma, Hematologic Neoplasms

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Lung Neoplasms

Stage II-IIIB Non-small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Carcinoma, Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Testing AZD9291 as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH-Subprotocol E)

Osimertinib With or Without Bevacizumab in Treating Patients With EGFR Positive Non-small Cell Lung Cancer and Brain Metastases

NEOLA

TARGET

A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)

CoC

SAVANNAH

Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone

Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm

MK-2870-003

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

ROSE

FLAME

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

Osimertinib, Surgery, and Radiation Therapy in Treating Patients With Stage IIIB or IV Non-small Cell Lung Cancer With EGFR Mutations, NORTHSTAR Study

OSTARA

Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC

Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer

A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR Mutant NSCLC

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC

Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

ORCHARD

Study of Osimertinib + SRS vs Osimertinib Alone for Brain Metastases in EGFR Positive Patients With NSCLC

Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance

FIOL

JMT101 Combined With Osimertinib in Patients With Stage Ⅲb-Ⅳ Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations

FLOWERS